We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Xenomics Presents Transrenal-DNA Technology Platform
Product News

Xenomics Presents Transrenal-DNA Technology Platform

Xenomics Presents Transrenal-DNA Technology Platform
Product News

Xenomics Presents Transrenal-DNA Technology Platform


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Xenomics Presents Transrenal-DNA Technology Platform "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Xenomics, Inc. has announced that it will present its Transrenal-DNA technology platform for the safe, accurate and noninvasive detection and monitoring of a range of diseases and genetic conditions, at the Bio InvestorForum 2005, 10 a.m. October 20, at the Palace Hotel in San Francisco, CA.

CEO Dr. Randy White will provide a corporate overview and highlights of Xenomics' Transrenal-DNA (Tr-DNA) technology which has broad applications for monitoring and/or detection of diseases and conditions including HIV, Tuberculosis, Down syndrome and other fetal genetic abnormalities. His presentation will be webcast simultaneously.

“Xenomics has continued to achieve its research and development milestones as we work toward commercializing our Transrenal-DNA medical diagnostic technology,” said Dr. White.

“Our primary mission is to transform our proprietary Tr-DNA platform technology into a new category of medical urine tests for an expanding range of diagnostic and health-monitoring applications, such as a simple but advanced urine test for pregnant women that effectively, accurately and easily screens for Down syndrome and other fetal genetic abnormalities.”

“Other applications of our Tr-DNA technology in our product development pipeline include urine sample tests for cancer and infectious diseases such as malaria and HIV.”

Among the participants and attendees expected at Bio InvestorForum 2005 are public and private equity investors, research analysts, investment bankers and senior-level industry executives focused on investment trends and business development opportunities in life sciences, according to organizers.

Xenomics' diagnostic technology is based on the noninvasive sampling of DNA material that passes transrenally, or through the kidneys, and is excreted in urine.

The Company is using the technology to develop safe and accurate medical testing products to provide a cost-effective, medically advantageous alternative to diagnostic methods now in use.

Advertisement